Geneva, Switzerland, November 23, 2023 – Abologix successfully completes the Innosuisse-funded program for the initial characterization of monoclonal antibody H225 (a blocker of JAM-C, Junction Adhesion Molecule C). Under this program, executed in collaboration with the University Hospital of Geneva (HUG), the preclinical efficacy and safety profile of H225 were assessed in several animal models of B-cell lymphoma. The excellent results pave the way for further development of the product.
top of page
Geneva, Switzerland, December 23, 2024 – Abologix has been awarded 100,000 CHF by the KICK FUND to progress its advanced preclinical...
Geneva, Switzerland, December 20, 2022 – Abologix nominates monoclonal antibody H225 (blocker of JAM-C, Junction Adhesion Molecule C) as...
Geneva, Switzerland, May 26, 2021 – Abologix has been named one of the winners of the Venture Kick stage III start up competition. This...
bottom of page
Comments